Report Package: Hot targets for empowered antibody and cell therapy technologies
Delivery costs do not apply or are included.
Ask a question about this product
Report Package: Hot targets for empowered antibody and cell therapy technologies
This package contains three reports analyzing
- BCMA,
- CD123 and
- CD22
as versatile and hot targets for the successful application of empowered antibody and cell technologies, including:
- Fc-Engineered Antibodies;
- Radioimmunotherapy;
- Immunotoxins;
- Antibody-Drug Conjugates;
- T-Cell Redirecting Bispecific Antibodies;
- Chimeric Antigen Receptor (CAR) T-Cells.
The reports describe and discuss
- Target background, scientific rationale & expression profiles;
- Preclinical proof-of-concept;
- Clinical experience;
- Competitive landscape;
- Drug or cell therapy profiles;
- Company profiles.
Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities
CD123: a paradigmatic target for immunotherapeutic treatment modalities
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page.
Report Package: Hot targets for empowered antibody and cell therapy technologies
Tables of Content
Report 1:
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities
Target Background
Target Antigen Expression Profile
Preclinical Proof-of-Concept
Clinical Indications & Treatment Options
Clinical Experience with BCMA-Targeted Treatment Modalities
Treatment Modalities & Competitive Landscape
- Drug & Cell Therapy Candidate Profiles
- CAR T-Cells
- Antibody-Drug Conjugate (ADC)
- T-Cell Redirecting Antibodies
Company Profiles
References
Report 2:
CD123: a paradigmatic target for immunotherapeutic treatment modalities
Target Background & Scientific Rationale
Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
Clinical Experience with CD123-Targeted Treatment Modalities
Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD123 Immunotherapeutics:
- Immunotoxins
- Naked Antibody
- Fc-Engineered Antibodies
- Antibody-Drug Conjugates
- T-Cell Redirecting Bispecific Antibodies
- Anti-CD123 CAR T-Cells
Company Profiles
References
ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics
Report 3:
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
Target Background & Scientific Rationale
Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD22 Immunotherapeutics
- Naked antibodies;
- Radioimmunotherapy (RIT);
- Immunotoxins (IT);
- Antibody-Dug Conjugates (ADC); and
- Chimeric Antigen Receptor (CAR) T-Cells.
Profiles of Companies with CD22-Targeted Immunotherapeutics
References
ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics